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ABSTRACT 
This paper concerns the patentability of short DNA sequence fragments known as 
expressed sequence tags (ESTs). The main objectives are to answer two key 
questions. The first question is whether ESTs are patentable subject matter under 
new guidelines for patentability in the United States and a new biotechnology 
Directive in the European Union. The second question is whether ESTs should be 
patentable. 
The paper argues that despite new guidelines in the US, ESTs are still patentable 
and that stricter provisions will have little long-term effect in stopping the barrage 
of claims that patent offices receive. Furthermore, that patent offices will be able to 
issue broad protection if applicants use broad wording in their claims. In the case 
of the EU, the paper argues that ESTs are patentable subject matter in that 
jurisdiction as well and that the new Directive does not bar broad EST claims. 
As to the second question the paper concludes that despite their patentability, ESTs 
should not be awarded broad protection because they have little practical utility. 
Moreover, such patents would have a detrimental effect on the whole biotechnology 
industry by impacting unduly on research through infringement and royalty issues. 
The paper concludes that the solution to the problem would be to create freely 
accessible databases but reasons that under current conditions that is an unlikely 
outcome. The paper argues that in any case patent offices should review and 
tighten their requirements to unequivocally resolve the issue. 
The text of this paper (excluding contents page, footnotes, bibliography and 
annexures) comprises approximately 14,442 words. 
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I INTRODUCTION 
Science and medicine are in a period of exciting and new technological 
development. The advent of the sequencing of the entire human genome 1 or genetic 
sequence paves the way for the creation of extremely effective medicines and 
innovative treatments and will help humans to understand more about themselves 
than ever before. "Once scientists know how each gene works and how it can 
malfunction, they can design sensitive diagnostic tests, find the genetic roots of 
diseases, customise medicines to each individual's unique genetic makeup- and 
maybe even replace defective genes with normal ones."2 Whether science and 
medicine can achieve this in the foreseeable future depends entirely on the law. 
Now more than ever the legal benefits and burdens will have the most influence on 
the way this technological innovation will develop. Intellectual property laws, 
especially patent law, will have the biggest impact on biotechnology in the future. 
The challenge for governments and the biotechnology industry is to balance the law 
such that there will be continuing research and development in medical, 
pharmaceutical and related industries but to allow the free flow and use of newly 
discovered information that is the basis of this research and development. 
The issue of human gene patenting is at the forefront of this legal debate but it is far 
from being resolved. New issues seem to appear almost weekly and add to the pile 
that lawmakers and the industry alike must deal with. One issue of continuing 
controversy and importance is the patenting of partial DNA (deoxyribonucleic acid) 
sequences known as expressed sequence tags (ESTs). In 1991 the United States 
National Institutes of Health (NIH) submitted thousands of these sequences for 
1 On 26 June 2000 scientists announced they had sequenced a rough draft of the entire human 
genome. See '"Book of Life ' ready to read" The Dominion, Wellington, New Zealand, 28 June 
2000, 5. 
2 Michael Lemonick "Victory for Venter", Time 17 April 2000, 55 . 
4 
patenting. Although the Patent and Trademark3 Office (PTO) had already issued 
numerous patents for DNA this case was different for the DNA sequences here did 
not code for entire functional proteins. Moreover, the sequences were obtained by 
using computers and required no meaningful human intervention. The NIH later 
withdrew its applications with many assuming they would be rejected for not 
having the requisite 'utility' .4 This seemed to be the end of the matter and it 
appeared that the PTO would not issue patents for such sequences. However, in 
October of 1998 the PTO issued a patent for Human Kinase Homologs (USP 
5817479), a partial DNA sequence in the form of an EST. The granting of this 
patent has renewed the debate with much vigour. Scientists and researchers are 
worried that allowing such patents will seriously affect the entire global 
bioindustry. 5 
Both the United States (US) and the European Union (EU) have amended their 
biotechnology patent policy with the issuance of new guidelines6 for the 
examination of patent applications in the case of the US and a new Biotechnology 
Directive7 in the case of the EU. The US issued new guidelines with the hope of 
curbing many EST patent applications by requiring a higher standard of utility and 
a more detailed written description of the invention or discovery. The EU issued its 
Directive to help clear up confusion regarding biotechnology patents. As this paper 
will consider, these amendments may have little or no effect in stopping EST 
applications and the subsequent issuing of broad patent protection. 
Biotechnology companies worldwide all have an interest in the decisions that the 
US and the EU make regarding patent policy. For example, Genesis, New 
Zealand's major biotechnology company, files DNA patent applications in both the 
3 Trade mark is one word in American English. 
4 60 US Fed Reg 36263 (1995) 
5 Japan Biotechnology Association Opinions Concerning Patentability of DNA Fragments, 
http://www.jba.or.jp/katudou/topics/news9904l9e.html, (last accessed 29 August 2000). 
6 64 US Fed Reg 71427 (21 December 1999) 
7 Council Directive 98/44 on the Legal Protection of Biological Inventions, 1998 OJ (L 213) 18-21 
[EU Directive] 
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US and the EU with the hope of securing rights in those jurisdictions to certain 
discoveries they have made.8 To remain competitive in a global market and to 
attract international investment, companies such as Genesis file EST patent 
applications in the US and the EU even though those jurisdictions have not fully 
determined the issue. They see this type of filing as "risk management"9 for they 
would rather spend the money in the hope that they might gain some intellectual 
property rights at a later stage rather than spend nothing at all and miss out. 
Resolving the EST issue is not an easy task but is one that countries who have a 
biotechnology industry must address. This paper will look at the patentability of 
ESTs and aims to answer two key questions, (1) whether ESTs can be patented 
under the new US guidelines and EU Directive and (2) on a broader scale, whether 
they should be patented. Part II of the paper gives a brief explanation of DNA and 
ESTs and their various functions. Parts III, IV and V examine the New Zealand, US 
and EU policies regarding ESTs respectively, to determine whether ESTs are 
patentable in those jurisdictions. The majority of analysis in these sections is on EU 
and US policy, where the bulk of law and practice is found. Part VI compares US 
and EU policy and part VII examines the second major issue of whether ESTs 
should be granted patent protection. 
II DNA AND ESTs 
A Genes 10 
To understand what an EST is it is first necessary to understand genes and DNA. 
DNA is found in virtually every cell of the human body. It is often referred to as the 
8 Email from Elizabeth Visser, Patent manager for Genesis Research and Development Corporation 
Ltd, New Zealand.(! September 2000) [Visser] 
9 Visser above n8. 
10 See generally Peter J Russell Genetics 5th ed (The Benjamin/Cummings Publishing Co, Menlo 
Park (CA), 1998), James Watson and others Recombinant DNA 2nd ed (Scientific American Books, 
New York, 1998), Benjamin Lewin Genes VI (Oxford University Press, New York, 1997). 
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blueprint for life for it contains all the information needed for a living being and is 
the starting point for the regulation of all the processes of the human body. DNA is 
a chemical compound in the shape of a double helix made up of four main 
chemicals or nucleotides called adenine (A), thymine (T), cytosine (C) and guanine 
(G). A always pairs with T, and C with G. Thus, one side of the DNA strand always 
forms a compliment of the other. The nucleus of a cell houses the DNA. It is found 
in the form of chromosomes of which there are 23 pairs. Chromosomes are long 
strands of the DNA chemical compound and it is on chromosomes that genes are 
located. Specific sections of DNA or a chromosome that have the capacity to 
synthesise or express proteins are called genes. Proteins are long chains of amino 
acids and form the basis of much scientific research and biomedical product 
development. 
Proteins carry out most of the processes of a cell and are what nearly all substances 
of the body are comprised of such as haemoglobin in blood and keratin in hair and 
nails. The cell produces proteins by 'reading' the nucleotide sequence of the gene 
using a ribonucleic acid (RNA) derived from the original DNA strand. Genes are 
often broken up by introns or sections of DNA that do not carry out protein making 
functions. When a cell makes a protein it sifts through the non-coding DNA and 
skips over the introns to find and copy the working part of the gene, producing a 
strand of RNA that carries the precise code for the desired protein. This strand is 
called "messenger RNA" (mRNA). Scientists have been able to extract this mRNA 
and from it make complimentary DNA (cDNA), which is a laboratory made version 
of a gene that contains only its information-rich (exon) regions. 11 
B ESTs 
ESTs are short sections of cDNA and were first used during the Human Genome 
Project (HOP), which began in the mid-1980s. The HOP was originally an 
11 
"What is cDNA sequencing?" http://www/sb.com/rd/dna_f.htm (last accessed 2 September 2000). 
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international project that aimed to sequence the entire genetic or nucleotide 
sequence of the human genome in an effort to discover genes and other useful DNA 
segments. Such discoveries would help enormously in medicine and science and 
have proved to be of use in fighting many diseases. There are approximately 3.1 
billion nucleotides in the human genome only a small percentage of which code for 
genes. 12 Much of the DNA serves, as yet, no useful purpose. 
In 1991, in an effort to discover the sequence of all nucleotide bases much faster, 
Craig Venter, an American Scientist working on the HGP at the time, used a non-
traditional approach to obtain the information. His method focussed on obtaining 
partial nucleotide sequences taken from cDNA and cutting them into overlapping 
pieces. He then reassembled the overlapping pieces to try to fashion a complete 
gene. He discovered however, that a lot of useful information could be gathered 
from a sequence of just a few hundred base pairs. There was enough information in 
the smaller sequence to point to the originating cDNA such that it could be used as 
a marker or an index point. The partial nucleotide sequences that Venter worked 
with he termed "expressed sequence tags". 13 Single genes may generate thousands 
of ESTs so there are potentially millions within the entire genome. 
C Functions and Uses of ESTs 
ESTs are useful in genomic 14 research because they help to find the specific gene 
from which they have originated. In many cases all that scientists have to work with 
is the HGP database or similar databases, which consist basically of continuous 
chains of the nucleotide bases A, T, C and G. Researchers discover ESTs usin.g 
gene-sequencing computers and it is a quick and extremely easy process. Once 
12 3-5% actually carry protein-making instructions. 
13 ESTs are only about 10% of the cDNA and contain around 300-500 nucleotide bases. 
14 "Genomics" is a relatively new term coined to define an area of science and medicine that focuses 
on the entire genetic sequence or genome of a species. By comparing sequences and other 
techniques, scientists are able to manipulate gene structure and function to provide radical new 
therapies to combat disorders and disease. See http://genomics.ucdavis .edu/what.html (last accessed 
30 July 2000). 
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isolated, they can use these as probes for discovering the complete gene from which 
the EST originated, but also as markers for specific locations on the genome or as 
to provide structural information relating to genes. 
ESTs do not define the function of a gene or a protein. In most cases where 
scientists have discovered ESTs using computer-sequencing techniques the EST 
has no known utility or function other than as a probe. Other downfalls of ESTs are 
that where discovery is by using computers the results are often less accurate than if 
found using traditional techniques. Moreover, since the nucleotide sequences are 
relatively short there is a much higher probability that the sequence will be similar 
or identical to an EST that belongs to another gene. This means that without further 
analysis a researcher will not be able to determine the gene from which it came. An 
EST in this case therefore, is not useful even as a gene marker or identifier. 
In summary, an EST is really only useful for preliminary research. The main use of 
ESTs is as probes or research tools. Although they code for proteins the proteins by 
themselves are often not valuable until they are joined together with the rest of the 
proteins formed by the whole gene. Basically, the science surrounding ESTs has 
not reached a developed stage whereby it contributes significantly to research. 
Scientists envisage however that this will change in the foreseeable future. 
III NEW ZEALAND POLICY 
Statutory law and case law concerning the patenting of DNA and living organisms 
in New Zealand are virtually non-existent to date. It is not surprising therefore that 
there is no policy concerning the patenting of ESTs. The Intellectual Property 
Office of New Zealand states that biotechnological matter can be patented as long 
as it fulfils the patentability criteria of novelty, industrial applicability, and non-
obviousness.15 However, this is as far as the matter has advanced in New Zealand as 
15 
See Intellectual Property Office of New Zealand website, httpJ/www.iponz.govt.nz 
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yet. Factors such as protecting indigenous populations and native flora and fauna 
have clouded the debate. 16 As such, there is likely to be little movement in the area 
until those issues have been resolved. 
More importantly however, is the fact that the US and the EU heavily influence 
New Zealand's patent policy in general. New Zealand is most likely waiting to see 
what those jurisdictions will do first. Nevertheless, the biotechnology sector in New 
Zealand, although small, is steadily growing. Recent reports concerning the use of 
certain gene and protein products in milk17 show there is innovation and 
development worthy of worldwide protection and the recent listing on the stock 
exchange of a New Zealand biotech company18 prove the industry is becoming 
profitable and globally competitive. New Zealand will have to either adopt a policy 
or create its own if it wishes to stay in the global race. Looking to the US and the 
EU for guidance is a wise option. 
IV US PATENT POLICY 
The biggest player in the biotechnology industry is the US and it is there that most 
of the debate regarding EST patents is ensuing. However, the consequences of the 
debate have far reaching effects. The EU, for example, is in the process of trying to 
align much of its biotechnology law with the US's in an effort to spawn industry, 
create employment and be more globally competitive. Any new development in the 
US therefore, will undoubtedly influence not only EU policy but also the policy of 
many other countries that have an established intellectual property regime and 
biotechnology industry, including New Zealand. Despite this factor, each 
jurisdiction may still maintain separate although similar laws. 
16 See for example Nin Tomas "The Convention on Biological Diversity: Are Human Genes 
Biological Resources?" New Zealand Environmental Law Reporter, July 1995, 127. 
17 "Milk Gene Research in Spotlight" The Evening Post, Wellington, New Zealand, 28 August 2000, 
3. 
18 "Cracker Listing Looms for Genesis" The Evening Post, Wellington, New Zealand, 15 September 
2000, 10. 
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A Legal History that Established Life Fonn Patents 
The US was the first jurisdiction to allow a patent for an EST. 19 This is probably 
due to its legal history concerning biotechnological intellectual property. The US 
has granted patents for living organisms since 1980. The case of Diamond v 
Chakrabarty ruled that "anything under the sun that is made by man" is 
patentable.20 The case concerned an application to patent genetically engineered 
bacteria that had the ability to break down oil. The majority of the court stated 
human intervention was the determining factor for whether something was 
patentable or not. Since then, the PTO has taken a liberal stance towards granting 
patents for life form inventions. Further case law and statutory developments have 
reinforced this position. For example, in Moore v Regents of the University of 
Califomia21 the majority of the Supreme Court of California held that a 
pharmaceutical product developed from a cell line taken without authority from a 
patient and then patented was not illegal or invalid. The patient, Mr Moore, had 
cells in his spleen that were very useful for further research and product 
development. Despite Moore having not consented for the doctors to remove his 
genetic material and experiment with it, the court still held that he had no property 
in material already removed from his body and further that he had no rights to the 
product developed from his genetic material. 22 This case reinforced the view that 
human material is patentable if there is some sort of intervention in the process. 
The only exception to life form patents is human beings themselves for under the 
13th amendment of the American Constitution that would amount to slavery.23 
Human DNA however, is patentable according to the PTO because isolating a gene 
19 (USP 5817479), Human Kinase Homologs. 
20 Diamond v Chakrabarty (1980) 447 U.S. 303,309. 
21 Moore v Regents of the University of California (1990) 793 P.2d 479. [Moore]. 
22 Moore however did succeed in a cause of action for the doctors having performed medical 
rrocedures without informed consent and also breach of fiduciary duty. See Moore above n21, 486. 
3 U.S. Constitution, amendment XIII, sl ("Neither slavery nor involuntary servitude ... shall exist 
within the United States."). 
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is a technical and artificial process and the protein, which the gene produces, has a 
known use. The isolated gene is an almost exact replica24 of what is found in nature 
but because it is extracted artificially that suffices the inventive step. Chemical 
compounds, which DNA is, are not novel if they are found in nature. However, 
purified preparations of naturally occurring chemicals meet the novelty requirement 
if they can be used in a way that the naturally found chemical could not be. Purified 
DNA sequences meet this requirement because isolation and purification of the 
DNA allows for uses that are not possible when DNA is in its natural state.25 
It is clear then, that in the US human DNA is patentable, but it is not so clear 
whether short DNA fragments that have minimal use, that are often extracted from 
unknown genes and that may not produce useful protein synthesising segments are 
patentable. This is the debate surrounding ESTs. 
B US Requirements for Patentability 
The US requires applications to fulfil four criteria before it will issue a patent.26 The 
first is that an invention must be "novel" or new in the sense that it must not be 
known or used before the application is filed. It must be "non-obvious" so that the 
invention cannot be a product or process already known or be an improvement 
easily made by someone trained in the relevant area. The invention must be 
"useful" in a practical sense. This means it must have an identified useful purpose. 
Finally, an invention must be described in sufficient detail such that one skilled in 
the area may use it for its stated purpose. This is often termed the "enablement" 
provision. 
24 The only difference is that junk DNA or introns have been removed 
25 John Murray "Owning genes: Disputes involving DNA sequence patents" 75 Chi-Kent L Rev 
243. [Murray] 
26 slOl, 35 USC. 
In terms of genetics therefore, an inventor must (1) identify a novel genetic 
sequence, (2) specify the sequence's product, (3) specify how the product functions 
in nature (its use) and (4) enable one skilled in the field to use the sequence for its 
stated purpose. 27 
Prima facie, is an EST based on these criteria patentable? The American Society of 
Human Genetics (ASHG) would argue "no". As to the first criterion, "novelty", the 
ASHG claims that there is absolutely nothing novel about the identification of 
ESTs, for an EST is simply a DNA sequence picked at random from a set of cDNA 
clones obtained either en mass by computers or otherwise through essentially 
standard published procedures.28 As to "non-obviousness" the idea of picking a 
large number of cDNA clones and using the sequence of a short piece of each as a 
genetic marker is an obvious approach and is practised widely within the scientific 
community.29 The most controversial aspect however, of allowing a patent for an 
EST is that of the "utility" requirement. "How can you patent something when you 
don't know what it is, much less what it will be used for?"30 The utility of an EST is 
as a probe or research tool that helps to identify the rest of the gene. However, 
researchers must undertake additional research before they can deduce the whole 
DNA sequence and its amino acid protein. Therefore, the utility of an EST can only 
ultimately be ascertained once further research has been completed. By this stage, 
the full cDNA sequence may be known in which case that is where the utility lies 
and where patent protection should be sought. "The EST is, at best, a starting point 
for further research, and should not be patentable."31 
27 Human Genome Project Information 
http://www.ornl.govffechResources/Human_Genome/elsi/patents.html (last accessed 24 August 
2000) 
28 American Society of Human Genetics Position Paper on Patenting of Expressed Sequence Tags, 
http://www.faseb.org/genetics/ashg/policy/pol-08 htm. [ASHG paper] . 
29 ASHG paper, above n28. 
30 254 Science 1991, 184-186. 
31 ASHG paper, above n28. 
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Despite these criticisms and concerns the PTO announced in 1997 that it would 
allow patents on ESTs. The utility of an EST would be based on its use as a probe.32 
Dr Leroy Hood of the University of Washington, Seattle said, "I am not completely 
surprised by this decision, because the patent office has done stupid things before, 
but I am dismayed. The idea that you can gain control of a gene by doing a little bit 
of sequencing is absolutely appalling."33 The PTO's justification was that it issued 
patents for works that were only useful as tools. "We give patents for screwdriver 
blades with a new slope everyday."34 This justification might seem sound but in the 
context of biotechnology and the effects that patents could have on future research 
and the industry in general, the PTO's argument is far less convincing. Each sector 
of industry has its own problems and demands so despite cross-industry arguments 
being useful they do not suffice as justifications in this context. 
Not surprisingly the PTO's decision provoked outrage in the scientific community 
so much so that the PTO decided to revise the guidelines it issues to patent 
examiners. While not technology specific the revised guidelines were really aimed 
at DNA and other biological patents, especially ESTs. The PTO issued a set of 
interim guidelines35 to clarify their position with respect to the "written description" 
and "utility" requirements under section 101 of the US Patent Code.36 The final 
guidelines are not expected to be substantially different from the interim guidelines, 
which patent examiners are already using, and will probably be issued sometime in 
the last quarter of 2000.37 
Despite the public's concerns and despite the PTO's attempts to appease them the 
new guidelines might not be all that effective in stopping (1) the barrage of EST 
32 See Science, l May 1998, 689. 
33 Sean Henahan "Patent Decision Shocks Genome Researchers" 
http://www.accessexcellence.com/WN/SU A09/est297 .html. (last accessed 29 August 
2000).[Henahan] 
34 Henahan above n33. 
35 64 US Fed Reg 71427 (21 December 1999) 
36 slOl, 35 USC 
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claims and (2) the legal patentability of such. Before such an assessment can be 
made however, it is necessary to look at the elements of patentability that the PTO 
will now require under the revised interim guidelines. 
1 Obviousness 
The PTO did not revise the "obviousness" standard but it still remains a mandatory 
consideration when granting a patent. The case of In re DeueI38 tested 
"obviousness" as relates to DNA. The Court of Appeals for the Federal Circuit 
(US) treated DNA as a chemical composition and applied established case law39 
relating to chemicals based on structural similarity when determining the non-
obviousness of a DNA molecule. The court went on to say that the existence of a 
general method of isolating DNA molecules was "essentially irrelevant"40 as to 
whether specific DNA molecules would have been obvious. Thus, the threshold for 
non-obviousness is rather low when it comes to DNA molecules. 
Despite the ASHG's concerns that picking a large number of cDNA clones and 
using the sequence of a short piece of each as a genetic marker is an obvious 
approach, Deuel would probably say that that was "essentially irrelevant". The 
court stated rather, that a case for obviousness is normally based on structural 
similarity between the claimed compound and a "prior art" compound.41 An EST 
claim would most probably suffice the non-obviousness requirement therefore 
because they are specific and unique sections of DNA. 
37 Julie Grisham "New Rules for Gene Patents" Nature Biotechnology Vol 18, September 2000, 921 
[Grisham]. 
38 In re Deuel 51 F 3d 1552. 
39 See Amgen v Chugai ( 1991) 927 F 2d 1200 (Fed Cir) 1207. 
40 Deuel above n38, 1559. 
41 Deuel above n 38, 1558. 
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2 "Written description" and the Revised Interim Guidelines 
The new written description guidelines are claimed to provide a general, systematic 
legal analysis of the case law on written description and explain the general 
principles governing compliance with the written description requirement of the US 
Patent Code.42 The general principle concerning the requirement is that it promotes 
the useful arts by ensuring that patentees adequately describe their inventions in 
their patent specification in exchange for the right to exclude others from exploiting 
the invention. The question examiners must ask is whether the application has 
described the invention in specific detail that one skilled in the art can reasonably 
conclude that the inventor was in possession of the claimed invention.43 
The biggest issue that involves the written description requirement is that EST 
patents, if granted, may be overly broad if described in general terms. This is where 
the new guidelines may have some influence. The guidelines do not add anything 
new to the law, but are rather a mere codification of cases such as Fiers v Revel44 
and University of Califomia v Eli Lilly & Co.45 Eli Lilly is a relatively recent case 
decided in 1997 which had the effect of tightening the written description 
requirements for DNA patent claims. Consequently, the PTO probably had no 
choice but to amend the written description requirement so as to take account of the 
ruling in Eli Lilly. Nevertheless, because no court has yet heard a case involving an 
EST and because the PTO has practically no decisions relating to ESTs as yet, the 
issue concerning the written description requirement for ESTs is largely 
unanswered. 
With regard to the written description in a DNA patent claim, the case of Fiers said 
that the conception of DNA, like the conception of any other chemical required a 
42 Stephen Kunin "Written Description Guidelines and Utility Guidelines" 82 J Pat & Trademark 
Off Soc'y 77, 78. [Kunin] 
43 Kunin above n42, 79. 
44 Fiers v Revel 984 F 2d 1164. [Fiers] 
45 University of California v Eli Lilly & Co 119 F 3d 1559. [Eli Lilly] 
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definition of the molecule other than by its functional utility. Conception does not 
occur until the inventor has "a mental picture of the structure of the chemical, or is 
able to define it by its method of preparation, its physical or chemical properties, or 
whatever characteristics sufficiently distinguish it."46 DNA applications therefore, 
must disclose the entire sequence of the segment to be patented as well as describe 
the method for obtaining the sequence and its utility. 
In the later case of Eli Lilly the PTO declined an application on the basis of an 
inadequate written description. The claim concerned a cDNA coding for rat insulin 
and involved a hypothetical situation, later revealed to be possible, showing how 
the cDNAs could be used to isolate human insulin. Although the claim contained a 
general method for obtaining human cDNA along with the amino acid sequence for 
human insulin, there was no information regarding the human cDNA's actual 
sequence. In upholding the PTO's decision the court stated that because a cDNA is 
not obvious unless its sequence is determined there is no sufficient written 
description unless the cDNA's sequence is fully disclosed as _well.47 Thus, there 
must be disclosure of the complete sequence of any claimed DNA sequence in 
order to meet the written description requirement. 
Some criticise Eli Lilly for placing an unnecessary burden on the manner in which 
the DNA compound may be described. However, this is countered by others who 
claim that the decision prevents patent holders overreaching by claiming more than 
they have disclosed. This is especially important in the case of ESTs because 
disclosure of an EST sequence may be followed by an attempt to claim the full 
gene from which it is derived. 48 
In reality, EST claims may in fact be overreaching and broad despite these tougher 
guidelines. It all depends on the wording of an application. ESTs by their very 
46 Fiers above n 44, 1169. 
41 Eli Lilly above n45 , 1567. 
48 Murray above n25 , 248. 
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nature are derived from a cDNA sequence, but their primary function is to probe for 
that particular sequence or for other homologous sequences. Accordingly, the 
particular cDNA sequence may be unknown at the time of application. It appears 
that the PTO would require disclosure of the cDNA sequence as well as the EST 
and other speculative sequences. However, applicants might be able to get around 
this requirement if they word their applications skilfully. 
To give an example, the use of words such as "gene" in the preamble of a claim 
might raise issues if one skilled in the art would understand that the term "gene" as 
used in the claims, in light of the disclosure in the specification, requires elements 
which are not sufficiently described.49 If a claimant mentions the gene from which 
the EST is extracted in the claim, then presumably that whole gene sequence must 
be disclosed as well as the EST sequence under the new guidelines, which codify 
the rule in Eli Lilly. 
One way to get around this provision would be to use the words "DNA molecule" 
rather than "gene".5° For example, an application that described the EST as "a DNA 
molecule comprising the EST of sequence X" would not require full disclosure of 
the DNA molecule because "one of skill in the art can readily envisage the genus of 
DNA molecules comprising sequence [X]."51 Consequently, in spite of the stricter 
requirements, applicants may still receive broad patent rights. The protection 
afforded by the patent is as broad as the protection would have been if the word 
"gene" were used instead. Arguably, the application that uses "DNA molecule" is 
far broader than one that uses "gene" yet the former application is seen as 
comporting with the written description requirement. 
49 Kunin above n42, 92. 
50 Stephen Bent and Paul Booth "Circuit's Aversion to Prophetic Claims May Limit Scope of an 
Expressed Sequence Tag Claim" http://www.foleylaw.com/PG/IP BIOT/genomics.html (last 
accessed 2 September 2000). [Bent] 
51 Kunin, above n42, 92. 
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To use the word "comprise" in a claim may also lead to broad protection. So a 
claim might be worded as "a DNA comprising the nucleotide sequence [X]". The 
manual of patent and examining procedures describes certain words and phrases 
and what their effect on a patent claim would be.52 For example "consisting of' 
excludes any element or step not listed in the claim. The phrase "consisting 
essentially of" limits the claim to the listed elements or steps "and those that do not 
materially affect the basic and novel characteristics of the claimed invention." 
However, the term "comprising" is open-ended and does not exclude additional 
elements or steps. Therefore, a patent claim, which reads "A DNA fragment 
comprising the nucleotide sequence GGCGG", would include any DNA sequence, 
including a 2000 base pair DNA sequence encoding a complete protein, which 
includes the sequence GGCGG at some point in the sequence.53 Consequently a 
claim that used the word "comprising" coupled with the words "DNA molecule" 
would suffice the written requirements but would still have a broad scope. The PTO 
has indicated that patent protection for claims worded this way, as long as the EST 
is fully disclosed, can be granted.54 The potential consequence of this is that the 
protection may, in effect, also encompass the entire cDNAs. An applicant would 
receive very broad protection with very little work and would be able to wait for 
other researchers to discover the original cDNA, if it was not already known, and 
claim that the EST patent covered that cDNA as well. 
The amended written description requirement may help in invalidating EST patent 
claims that applicants have already filed because many will have no sufficient 
disclosure of entire gene sequences if such genes are mentioned. On the other hand, 
they will not stop new applications that are reworded more cleverly and carefully to 
take account of the new provisions. The revised written description regulations 
therefore, will have little effect on redrafted claims and will not stop examiners 
52 Section 2111.03 US Department of Commerce, Patent and Trademark Office, Manual of Patent 
Examining Procedure (6th ed 1996) 
53 Dorothy Auth "Are ESTs Patentable?" 15 Nature Biotech 911, (1997). 
54 Dan Goodin, "Gene Genie", Recorder, 20 August 1997, 1. 
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being able to award EST patents with broad protection, assuming they suffice the 
other criteria, the next of which to consider is "utility:" 
3 "Utility" and the Revised Interim Guidelines 
When the PTO asked for comments on its guidelines many of the replies heavily 
criticised the patentability of ESTs on fairness and policy grounds.55 The major 
concern was with respect to the utility requirement. Many of the comments claimed 
that sufficient patentable utility had not been shown when the sole disclosed use of 
an EST is to identify other nucleic acids whose utility is not known, and the 
function of the corresponding gene is not known. 56 The result would be that patents 
would be granted for non-substantial utilities, which is contrary to established case 
law. 
In the case of Brenner v Manson57 the US Supreme Court required disclosure of 
"specific utility" and of "substantial utility .... where specific benefit exists in 
currently available form". And in the case of In re Ziegler, 58 the Court of Appeals 
for the Federal Circuit required that a specific and substantial or practical utility for 
an invention be disclosed as a condition of meeting the practical utility requirement 
of section 101 of the US Patent Code. 
The new interim utility guidelines issued to examiners are different from previous 
guidelines in two substantial ways. The first is that examiners are urged to 
determine whether an asserted utility is specific and substantial whereas before the 
emphasis was on whether an asserted utility was credible. So in the case of an EST 
application, instead of determining whether the stated use is credible, the emphasis 
is on whether the stated use is specific and substantial. The credibility requirement 
is still an important consideration however, and is based on whether a person of 
55 Kunin, above n42, 93. 
56 See US PTO website, http://www.uspto.gov/web/offices/com/sol/comments/utilguide/index.html 
57 Brenner v Manson (1966) 383 U.S. 519, 534-35 [Brenner] . 
20 
ordinary skill in the art would find a particular assertion credible. For example, the 
question to ask would be whether a person skilled in genomics would find the 
assertion that an EST would have probative value in determining whole gene 
sequences was credible. If the answer to that question was "yes" then an application 
could not be refused on the grounds of utility under the previous guidelines. A 
claim under the new guidelines however, would have to detail substantial and 
specific use as well as have a credible use for the invention, which in the case of 
ESTs, although possible, could be a more difficult task. This is mainly due to the 
fact that "use as a probe" would, on the face of it, not suffice the credible, specific 
and substantial requirements because such use is not really substantial. 
It can be assumed that for the patent granted over the Human K.inase Homolog EST 
in 1998,59 and thus under the old guidelines, that the examiner in that case decided 
that the stated use was credible. Reading through the detailed application it appears 
that the use described is only as a probe. The application was very specific in that it 
identified the gene and the proteins. Nevertheless, an issue lies in whether the claim 
pointed to a substantial use. If there were no substantial use the PTO granted the 
patent for a credible and specific use but arguably not for substantial use, which 
Brenner and Ziegler require. 
Brenner further refines the utility requirement. A mere speculative or potential 
utility that does not provide specific benefit to the relevant public does not meet 
patentability requirements.60 
Whatever weight is attached to the value of encouraging disclosure and of 
inhibiting secrecy, we believe a more compelling consideration is that a 
process patent in the chemical field, which has not been developed and 
pointed to the degree of specific utility, creates a monopoly of knowledge, 
which should be granted only if clearly commanded by the statute .... The basic 
quid pro qua contemplated by the Constitution and the Congress for granting a 
patent monopoly is the benefit derived by the public from an invention with 
58 In re Ziegler (1996) 992 F.2d 1197, 1201 [Ziegler]. 
59 USP 5817479 
60 Brenner above n57, 534. 
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substantial utility. Unless and until a process is refined and developed to thls 
point- where specific benefit exists in currently available form- there is 
insufficient justification for permitting an applicant to engross what may 
prove to be a broad field .... Congress intended that no patent be granted on a 
chemical compound whose sole "utility" consists of its potential role as an 
object of use-testing .... Thls is not to say that we mean to disparage the 
importance of contributions to the fund of scientific information short of the 
invention of somethlng "useful," or that we are blind to the prospect that what 
now seems without "use" may tomorrow command the grateful attention of 
the public. But a patent is not a hunting license. It is not a reward for the 
search, but compensation for its successful conclusion. 
On this reasoning then, there are doubts as to why the PTO allowed the Human 
Kinase Homolog EST patent considering there was only a generalised utility. 
Despite PTO guidelines at the time placing an emphasis on credibility there was 
still well established case law that stated generalised utility was not sufficient to 
fulfil the requirements of a patent monopoly grant. 61 Furthermore, it is arguable that 
use as a mere probe or marker is not a specific benefit in currently available form. 
Only after further research is undertaken will such benefit exist. Debatably, this 
patent is against stated law and might not stand up to a revocation claim. 
In general, ESTs do not have a specific and substantial utility that provides real 
world value and a specific benefit to a relevant class of people. Their utility is only 
general because further research must be undertaken before a specific and 
substantial benefit exists. Therefore, under Brenner the PTO should disallow EST 
patent claims that do not provide sufficient detail as to substantial and specific use. 
The revised guidelines add nothing new to the law; they merely clarify what was 
emphasised in Brenner and subsequent cases. Previous PTO guidelines have been 
inadequate therefore, in light of Brenner and related decisions. 62 
The second way that the guidelines differ from previous directives is that they place 
an emphasis on "throwaway" utilities, which would not suffice statutory 
requirements either. A "throwaway" utility is a way of trying to comply with the 
61 Brenner above n57 and Ziegler above n58. 
62 Ziegler above n58 and In re Kirk 376 F.2d 936. 
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utility requirement. It asserts a credible utility but is much too generalised and not 
directed at the real world or intended use of the invention. Examples often given are 
saying that a complex invention is for use as landfill or that a genetically altered 
mouse is snake food.63 
This new emphasis is no different from requiring a specific and substantial utility as 
discussed above. Either the PTO is urging its examiners to be wary of such asserted 
uses or it is being overly cautious in its approach. A "throwaway" assertion is, and 
always has been, against the rule stated in Brenner; the new guidelines only clarify 
the situation. In previously allowing "throwaway" utilities the PTO was awarding 
patents contrary to the established law. 
Stating the use of an EST as a probe might arguably be a "throwaway" utility. 
However, because the PTO has announced that they will consider applications that 
state use as a probe this problem is seemingly done away with. If such were a 
"throwaway" utility it would automatically be rejected. It . will be necessary 
however, to further define use as a probe to fulfil the "specific and substantial" 
requirements. 
The future of applications for EST patents that describe utility in terms of use as a 
probe to find whole gene sequences remains uncertain in the least. While such 
ESTs always would have been unpatentable due to lack of specific and substantial 
utility under Brenner, the new guidelines are a much clearer interpretation of this 
rule and are probably as strict as they always should have been. Examiners who 
might not always have been aware of established case law will have a more 
definitive framework with which to work. 
Of the 20 OOO or so applications at the PTO awaiting examination many might fail 
due to the new guidelines. Under the stricter rules, EST claims that generally state 
63 Douglas Steinberg, "Biotech faces evolving patent system" The Scientist 14[5], 6 March 2000. 8 
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use as a probe, which state that the sole immediate utility is for further research or 
that state further knowledge is required before any specific benefit could be derived 
from the fragment would fail the utility requirement for not referring to a 
substantial use rather than because such uses are "throwaway" utilities. Thus, the 
PTO could issue no patent. According to John Doll, the director of biotechnology 
patent examination at the PT0,64 
Just to say 'I have a piece of DNA, and it is useful as a gene probe' isn't good 
enough to pass the [new] utility test. What you're going to have to say is 'My 
particular piece of DNA probes for this particular gene, disease state, or 
location on a chromosome.' If you're going to be patenting a chromosome 
marker, you'll have to tell us what you're marking. 
These stricter guidelines do not sit well with both opponents and proponents of EST 
patents. Opponents claim they do not go far enough in unequivocally preventing the 
granting of such patents whereas proponents claim they go too far. Elizabeth 
Weimar, an administrative judge at the PTO, says it is not clear whether the use of 
the word "substantial" in the new guidelines requires a higher standard considering 
that courts have interpreted "substantial utility" to mean "practical utility" in certain 
cases. 65 ESTs can and often do have a practical utility. The argument against 
Weimar's concern is that the PTO would not have amended its guidelines to require 
a higher standard if that was not its intention and also that case law already requires 
a high standard. The move to change the guidelines was spurred on by public 
comments that they were too lax. The higher standard the PTO requires reflects 
these public concerns. 
Another fear is that the higher utility standard "will be a disincentive to people 
filing patent applications who are pioneering new technology areas."66 This is a 
valid concern but not for the debate on ESTs because EST technology at its present 
standard has an extremely low level of inventiveness. Any newer, useful 
http://www.the-scientist.com/yr2000/mar/stei nberg_p8 _ 000306.htm1 [Steinberg] 
64 Steinberg above n63. 
65 Steinberg above n63 . 
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development concerning ESTs would probably pass the inventive threshold and 
would have a high chance of receiving patent protection. In any case, if a pioneer is 
worried that his or her invention might not receive protection, despite initial fees, 
the benefit of at least filing a patent far outweighs not filing one at all. The higher 
standard might be a burden on some but is far short of a disincentive not to invent 
at all. 
Whether ESTs will pass the utility test remains to be seen. However, it is entirely 
possible that an EST could suffice the requirements. As long as there is a credible, 
specific and substantial use stated then the PTO will award protection. Despite fears 
that use as a probe is not substantial it looks as though the PTO will award patents 
on that basis. 
4 Enablement 
As long as applicants word their claims sufficiently and with proper detail, the 
enablement provision will be easy to fulfil. This provision is closely connected to 
the written description requirement but enablement can still be satisfied even if the 
written description is lacking in someway such as non-disclosure of the full DNA 
sequence from which an EST is derived. ESTs can easily suffice this requirement if 
they allow one skilled in the field to use the sequence for its stated purpose, which 
is not an onerous task. A claim must state how to create the EST, where to find it 
and how to use it. As ESTs are relatively short and because of effective computer 
technology, fulfilling the enablement procedure is a relatively straightforward 
procedure. 
66 Steinberg above n63 . 
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C US Summary 
To summarise thus far then, EST type claims have been patentable in the US by 
evidence of the Human Kinase Homolog patent and four other patents67 that did not 
specifically term their inventions as ESTs and that the PTO granted before a 
revision of their guidelines. There is no specific prohibition on the patenting of 
such DNA sequences but after the PTO's issuance of the revised interim guidelines, 
obtaining a patent on such nucleotide fragments, although still allowable, will most 
likely involve a little more effort. The new guidelines do raise concerns both for 
and against the higher utility standard but on balance the higher standards are a 
better reflection of the case law on the subject. 68 
1 The new standards will not stop EST applications or broad claims 
The impetus behind the revision of the patent guidelines was public comment that 
feared that awarding an EST patent would (1) be overly broad and (2) would be 
harmful to research. The PTO in trying to allay some of the fears made patent 
requirements stricter in the hope of curbing applications and culling out many that 
had already been filed. In 1996, the Office had already tried to restrict claims by 
limiting the number of DNA sequence claims to ten per application claiming it did 
not have the resources to fully examine each claim within a reasonable timeframe.69 
However, this has not stopped the barrage of claims from every biotechnology 
company around the world wishing to join in the race. Despite the PTO having 
awarded only five EST type claims thus far, companies do not want to risk their 
chances. To date there are about 20,000 applications relating to gene patents, many 
of which are probably ESTs, waiting to be examined by the PT0. 70 A major 
genomics company, Incyte, also aims to patent more than one million gene related 
67 US Patents numbers 5552281, 5654173, 5969123, 5969125. 
68 See Brenner above n57, Ziegler above n58 and In re Kirk 376 F.2d 936. 
69 ''PTO Announces New Policy to Process Gene-Sequence Biotechnology Patents" 
http://www.uspto.gov/web/offices/com/speeches/96-21.txt (last accessed 10 July 2000). 
70 Grisham above n37, 921 
inventions and cliscoveries. 71 Restricting the number of DNA sequences to ten per 
application, therefore, has had little effect. The new guidelines may also have little 
or no effect on refiled or new claims. In all likelihood the effects will be obvious 
but will be short lived once applicants come to terms with the new requirements. 
The guidelines may invalidate many of those claims already filed but will not stop 
those that employ skilful wording, such as not referring to the gene from which the 
EST came but rather classing it as a distinct DNA molecule and using "comprising" 
language. 
If an EST application is non-obvious, which most will be according to the 
requirements of In re Deuel,72 has a sufficient written description that discloses 
entire sequences of genes referred to in the claim or uses clever wording such as 
"DNA molecule" instead of "gene", shows credible, specific and substantial utility, 
which might be easier to do than at first glance if the PTO allows use as a probe to 
suffice the utility test despite the case law, and the written description allows one 
skilled in the field to use the sequence for its stated purpose, then a patent should be 
granted. Potentially, the patent may be broad and far-reaching and may cause many 
legal problems regarding infringement. 73 Nonetheless the claim should still be valid 
because on the face of the new guidelines and PTO statements there is no legal bar 
to the PTO awarding such protection. 
The new guidelines do not go far enough in helping to resolve the EST debate. 
They raise the bar a little but are not sufficient in stopping broad claims or stopping 
thousands or even millions of new EST applications that could have disastrous 
results for future research and the biotechnology industry. This does not mean to 
say that ESTs should not be patentable at all rather, present guidelines are too easy 
to fulfil so that even the most basic of discoveries that will have minimal benefit to 
the scientific community can receive patent protection. The effects of this could 
71 Michael Lemonick "Victory for Venter", Time 17 April 2000, 55 . 
72 Deuel above n38. 
73 Discussed in part VII below, 39. 
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have a potentially detrimental effect on the future of genomic research. 74 ESTs may 
have a more beneficial use in future years when technology has progressed, so a 
complete ban on patenting these sequences may be premature. Furthermore, a 
minority of EST claims actually do serve uses other than as probes and in their 
present form are justifiable. However the bulk of claims do not fit this description. 
The human kinase homolog and four similar EST related patents show that the PTO 
has been willing to award broad protection. The PTO should further refine their 
requirements and guidelines to remedy the problem or even consider separate 
guidelines or a sui generis system for DNA and gene related patents so that other 
technologies are not caught up in tougher provisions. 
V EU PATENT POLICY 
Europe has seen a different evolution of its patent laws with respect to living 
organisms and DNA. In 1973, in an effort to harmonise patent laws in the European 
Community, eleven European nations75 joined together to create the Convention on 
the Grant of European Patents,76 commonly known as the EPC. This centralised 
patent application and granting processes throughout Europe and created advisory 
bodies to set official policy. Article 53(b) of the EPC prohibited the patenting of 
plant and animal varieties. However, there was no guidance as to what constituted 
an animal variety and when American scientists applied to patent a genetically 
altered mouse (the Harvard oncomouse) an ongoing legal saga ensued, which as yet 
remains unresolved. 77 
74 See below part VII(b), 44. 
75 Current members of the EPC which includes some non-EU nations are: Austria, Belgium, 
Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, The 
Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom. 
76 Convention on the Grant of European Patents, 5 October 1973, 1 BDIEL 985 [EPC] . 
77 See Tl9/90 HARVARD/fransgenic mouse (OJ 1990 476) and OJ 1992 588. 
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The EPC remained silent as to DNA sequences and other life forms, so it was 
assumed they were patentable merely due to the fact that there was no express 
prohibition.78 The only guidance was the "ordre public" provision in article 53(a) 
which allowed member states to deny a patent contrary to morality. This provision 
in itself caused confusion, so much so that the European Patent Office (EPO) and 
the EU in general took a new approach to the whole biotechnology issue. The 
European bioindustry was lagging somewhat compared to that of the US so in the 
interests of economic growth, as much as for the sake of individuals and 
corporations within the EU, the governing bodies started working towards a more 
definitive and holistic approach to the problem. There was also a fear that without a 
unified approach individual states within Europe would change their laws banning 
DNA and related patents to the detriment of the competitive EU economy. The EU 
therefore began working on a Biotechnology Directive that would harmonise 
member states' laws concerning the patenting of life form inventions. 
A Relaxin 
While the member states and the biotechnology industry were fleshing out the 
provisions of the Directive the EPO Opposition Division heard a claim against the 
awarding of a patent for H2-relaxin, a product derived from human DNA. In 
Howard Florey!Rela.xin79 the Opposition Division heard arguments claiming DNA 
was not patentable due to a number of reasons. The opponents to the patent argued 
that the patent lacked novelty because the gene encoding relaxin was always 
present in the female body. The Opposition Division's answer to this was that the 
sequence was actually a cDNA and hence artificially isolated so it was not found in 
nature. As the sequence encoding relaxin was unknown until it was isolated it 
sufficed the novelty aspect of European law.80 The opponents further claimed that 
the patent could not fulfil the inventive step aspect because the sequence was 
78 Philip Grubb Patents for Chemicals, Pharmaceuticals, and Biotechnology: Fundamentals of 
Global Law, Practice and Strategy (1999, Oxford University Press, Oxford) 248, 254 [Grubb]. 
79 Howard Florey!Relaxin [1995] EPOR 541 (Opp Div EPO) [Relaxin] 
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isolated in a conventional way. The reply to this was that as the sequence was 
found to be novel, the way in which it was extracted did not matter. As the 
sequence did not come close to any prior art it sufficed the inventive step.81 The 
opponents further argued that to patent DNA would be against the article 53(a) 
morality provisions of the EPC (1) because the tissue was extracted from pregnant 
women and (2) it was a return to slavery. The Opposition Division relied on the 
EPO Guidelines, which stated that in looking at morality82 
A fair test to apply is to consider whether it is probable that the public in 
general would regard the invention as so abhorrent that the grant of patent 
rights would be inconceivable. If it is clear that this is the case, objection 
should be raised under article 53(a); otherwise not. 
The Opposition Division "emphatically" rejected the opponent's arguments. 83 
"[T]here was nothing immoral about the isolation of the relaxin DNA"84 and the 
slavery argument showed a fundamental misunderstanding of the effects of a 
patent.85 
DNA is not life, but a chemical substance which carries genetic information 
and can be used as an intermediate in the production of proteins which may be 
medically useful. The patenting of a single gene has nothing to do with the 
patenting of human life. Even if every gene in the genome were cloned (and 
possibly patented), it would be impossible to reconstitute a human being from 
the sum of its genes. 
Relaxin showed the willingness of the EPO to grant DNA patents and showed how 
DNA sequences would fulfil patent criteria. Even before the EU Directive came in 
to play DNA was patentable subject matter. Nevertheless, much like in the case of 
the US, the law at the time was controversial and unclear. With the advent of ESTs 
80 Relaxin, above n79, para 4. 
81 Relaxin, above n79, para 4.6.1. 
82 European Patent Office Guidelines Chapter IV, 3.1. 
83 Relaxin, above n79, para 6.3. 
84 Relaxin, above n79, para 6.3.2. 
85 Relaxin, above n79, para 6.3.3. 
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the issue became even more contentious. The EU therefore was in much need of a 
precise statement on what the law would be. 
B Biotechnology Directive 
After much debate and many drafts the EU issued a Biotechnology Directive86 that 
all members of the EPC accepted in 1998. The Directive gave until 30 July 200087 
for member states to implement minimum standards into their intellectual property 
laws to take account of the principles enumerated in the Directive.88 The most 
important provision in relation to genes and gene sequences is article 5 of the 
Directive, which expressly states that human genetic material is patentable. 
(1) The human body, at the various stages of its formation and development, 
and the simple discovery of one of its elements, including the sequence or 
partial sequence of a gene, cannot constitute patentable inventions. 
(2) An element isolated from the human body or otherwise produced by means 
of a technical process, including the sequence or partial sequence of a 
gene, may constitute a patentable invention, even if the structure of that 
element is identical to that of a natural element. 
(3) The industrial application of a sequence or a partial sequence of a gene 
must be disclosed in the patent specification. 
The European policy has for the last 20 years remained unclear and uncertain. The 
Directive aims to change this and provide some certainty in the biotechnology field. 
Human genes if isolated are patentable as long as they are reproduced by technical 
means. 
The recitals to the Directive contain important observations when it comes to the 
patenting of partial gene sequences and ESTs. Recitals 22 to 24 state: 
86 Council Directive 98/44 on the Legal Protection of Biological Inventions, 1998 OJ (L 213) 18-21 
[EU Directive]. 
87 At that date the Netherlands and Italy had still not amended their laws. See 
http://www.sib.it/engsib/novita/pat/l 00800.htm (last accessed 15 August 2000). 
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(22) Whereas the discussion on the patentability of sequences or partial 
sequences of genes is controversial whereas, according to this Directive, the 
granting of a patent for inventions which concern such sequences or partial 
sequences should be subject to the same criteria of patentability as in all other 
areas of technology: novelty, inventive step and industrial application whereas 
the industrial application of a sequence or partial sequence must be disclosed 
in the patent application as filed. 
(23) Whereas a mere DNA sequence without indication of a function does not 
contain any technical information and is therefore not a patentable invention. 
(24) Whereas, in order to comply with the industrial application criterion it is 
necessary in cases where a sequence or partial sequence of a gene is used to 
produce a protein or part of a protein, to specify which protein or part of a 
protein is produced or what function it performs. 
These provisions make it clear that ESTs are patentable in the EU as long as there 
is a known function for the EST. The same criteria that are applied to other areas of 
technology, namely novelty, 89 inventive step9() and industrial application,91 are the 
bases for an EST patent claim. An application must also disclose a specific use 
before it will be considered for protection. Relaxin, although a case that concerned 
a whole gene, would lend weight to EST patentability. The biggest obstacle 
however, would be the industrial applicability criterion. 
As yet, the EPO has granted no patents for ESTs in the EU. 92 It has also received far 
fewer applications, if any, due to a different application regime. ESTs are limited to 
one per application so it would be prohibitively expensive to file a separate 
application for each EST, especially when it still remains unclear if the EPO will 
even grant such patents. Secondly, applications must be published 18 months from 
the priority date, which is another disincentive if no protection is yet available. 93 
88 EU Directive above n86, article 1(1) and article 15(1). 
89 Article 54 of the Convention on the Grant of European Patents, 5 October 1973, l BDIEL 985 .S 
[EPC]. 
9<l EPC above n89, article 56. 
91 EPC above n89, article 57 . 
92 Claire Baldock "Report Q 150: Patentability requirements and scope of protection of expressed 
sequence tags (ESTs), single nucleotide polymorphisms (SNPs) and entire genomes" EIPR 2000 
22(1) 39, 40 [Baldock] 
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The EPO issues most biotechnology patents in Europe94 but until recently did not 
even have to take note of the EU Directive because it was created under the EPC 
which is not a direct organ of the EU.95 The Directive's provisions still do not bind 
the EPO but its Administrative Council has amended the EPC Implementing 
Regulations to take account of the Directive.96 The new rules provide that the 
Directive "shall be used as supplementary means of interpretation," including the 
recitals. 97 The EPO notes however that98 
Although the principles set forth [in the Directive] regarding the patentability 
of biotechnological inventions are based on the relevant provisions of the EPC 
and essentially reflect current practice as developed by the Office and its 
boards of appeal in applying the Convention, some extensions and 
clarifications are required in this area to ensure that the patentability 
provisions of the EPC also continue to be interpreted in keeping with the 
Directive. 
Thus, despite the new Directive, some aspects including the issue of EST patents 
are still unresolved in the eyes of the major granter of biotechnology patents, the 
EPO. 
C British Working Group Opinion on Patentability of ESTs 
In relation to a series of questions set by the International Association for the 
Protection of Industrial Property regarding the issue of EST and related patents in 
the EU, a British working group gave its opinion in a recently published paper.99 
The overall impression the paper gives is that ESTs should be patentable in the EU. 
93 Grubb, above n78, 248. 
94 Baldock, above n92, 40. 
95 Grubb, above n78, 255 . 
96 Baldock, above n92, 39. 
97 Baldock above n92, 40. 
98 Baldock above n92, 40. 
99 Baldock, above n92. 
33 
1 Morality 
The first question asked whether allowing EST patents would be contrary to the 
"ordre public" or morality provision of the Directive. 100 The answer the group gave 
was "no", ESTs are not against morality and have not been included in a non-
exhaustive list in the Directive that details such things as a ban on human cloning. 101 
Furthermore, Relaxin already decided that DNA patents were not against the 
morality provisions of the EPC, which are reflected in the new Directive. 102 
2 Obviousness 
The British group advised that the usual standard of obviousness should apply to 
EST patents, which in English law at least is the "notional skilled man". 103 Despite 
the purely mechanical act used to obtain ESTs the group states that it might not be 
obvious if the utility of the EST is described as having some benefit other than as a 
mere probe. 104 Implicit in this statement is that obtaining ESTs routinely and then 
stating their use as a mere probe would be obvious and would fail the obviousness 
test. Thus, ESTs that do not further define utility other than use as a probe would 
not receive patent protection. Despite such applications failing the obviousness test 
the British group, in defining utility, states that use as a mere probe would satisfy 
the normal utility requirements and that EST claims that stated use as a probe 
should not fail for utility reasons (discussed below). The fallacy in this argument is 
that as the group states, obviousness is closely linked with utility and this is 
recognised in EU case law. 105 If the group is advocating that use as a mere probe 
should satisfy utility but that mechanically generated ESTs that state use as a mere 
probe would fail obviousness then all such ESTs would not be patentable. The 
100 EU Directive, above n86, article 6. 
101 EU Directive, above n86, article 6(2)(a). 
102 EU Directive, above n86, article 6. 
103 See for example Dow Corning Corporation 's Application [1969) FSR 338 (Pat App Tr). 104 Baldock, above n92, 41. 
105 Agrevofiriawle Herbicides [1996] EPOR 171 and Mycogen [1998) EPOR 114. 
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group should be advocating a higher standard of utility so that ESTs will not fail the 
obviousness test. 
3 Industrial applicability/ utility 
As to the level of utility required for an EST patent or industrial applicability as it is 
termed in the EU, the group concluded that examiners should apply the same level 
that is required in other areas of technology. It admitted that this was a fairly low 
threshold but that present law required no more. The UK case of Chiron v Murex & 
Organon Teknika. 106 invalidated a patent claim to a polypeptide sequence because 
part of the claim covered "an almost infinite number of polypeptides which are 
useless for any known purpose." On this logic the British group reasoned that as 
ESTs have a known function they cannot be "useless for any known purpose" and 
that they are likely therefore, to be industrially applicable. 
Industrial applicability or utility is the main issue in relation to granting an EST 
patent in the EU. As the EPO has not yet issued a pate:1t for an EST and as no court 
has yet heard an appeal regarding an EST the issue is very much unanswered. Will 
the EU require the same level of utility that the US insists on or should the standard 
remain the same as for other areas of technology as the British group claims it 
should? 
Presently, the EPO standards that mirror the Directive require that "the industrial 
application of a sequence or a partial sequence of a gene must be disclosed in the 
patent application." 101 In discussion of this rule the EPO further specifies that 
"where such sequences are the subject matter of an invention, it is necessary to 
indicate in particular what function is performed by the sequence and the protein 
built from it." 108 There is no explicit statement however, that use of an EST as a 
106 [1996] FSR 153. 
107 EPO rule 23e (3) 
108 EU Directive, above n86, recital 24. 
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probe or research tool will not suffice the industrial applicability requirement. 
Arguably, an applicant could indicate that a protein from a sequence could be used 
as a probe and that would satisfy a "particular function". The guidelines and rules 
are far from adequate in defining utility. Despite the recitals to the Directive that 
state that "a mere DNA sequence without indication of a function ... is ... not a 
patentable invention," 109 and further that "it is necessary in cases where a sequence 
or partial sequence of a gene is used to produce a protein or part of a protein, to 
specify which protein or part of a protein is produced or what function it 
performs," 110 the issue could go either way. Prima facie, an EST application that 
states some kind of function and that specifies a protein should be patentable. Yet it 
is not clear whether this is an EPO objective or not. Presumably, since the office 
has issued no such patents it does not agree that mere probes suffice utility or 
industrial applicability. 
The EU would probably be better off requiring a higher standard for industrial 
applicability than normal when it comes to EST patents. As there is no 
jurisprudence on the subject and as the guidelines regarding ESTs are not as 
developed as the US' s it would be a dangerous thing for the EU to issue patents that 
will more than likely cause considerable confusion, be challenged in the courts at a 
later date and that would conflict with US law. It would be better to try to at least 
start to resolve the issue with more detailed guidelines. As the British discussion 
highlights, there are diverse and contradicting views on the present Directive and 
EPO guidelines. Further clarification is needed to remedy this problem. 
VI COMPARISON OF US AND EU POLICIES 
The most evident observation that can be made in comparing the two policies is 
that the US is at a more advanced stage when it comes to patentability of ESTs. 
Although the issue is not resolved in America it is closer to resolution than in the 
109 EU Directive, above n86, recital 23 
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EU. There is also a more developed jurisprudence when it comes to the 
requirements of DNA patents in the US. That is not to say that the EU has failed in 
any sense, rather EST patentability has only recently become an issue in the EU 
whereas it has been pondered for some time in the US since the NIH filed many 
EST applications in 1991. 
The main issue in EU law like the US is the utility or industrial applicability 
requirement. At first glance it appears that the EU would possibly allow mere 
probes to suffice for industrial applicability given the British group's reasoning. It 
would therefore seem easier to gain patent protection in the EU than in the US 
purely on the utility issue. However, as no patents have yet been issued it is too 
early to unequivocally state what EU law is. The EU may well decide to follow the 
US's lead and clearly tighten the requirements. 
If the EPO does issue patents on present standards then it will be far easier to 
receive patent protection for ESTs in Europe than in America. There is no 
indication as yet as to which way the EU will go. Perhaps in a year or so when the 
EPO has examined EST applications will their stance be known. 
The EU is in a better position also to watch and learn from US successes and 
failures. Maybe that is what it is observing at the moment. This approach would 
save much time, effort and litigation by waiting until the major player has decided 
what it will do. Nevertheless, it will have to confront the issue at some stage if it 
wishes to remain globally competitive in the biotechnology industry. Uncertainty is 
probably far worse than a clear statement that bans EST patents. 
The EU has the added difficulty of the morality or "ordre public" provisions 
contained in the Directive. 111 Despite the ruling in Relaxin there is room for higher 
courts to re-examine the morality provisions, especially if public feeling towards to 
110 EU Directive, above n86, recital 24. 
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gene and DNA issues sours. This morality provision might unnecessarily hinder the 
debate in the EU whereas it is not even an issue in the US. 
In summary then, the US's position is more favourable despite some anomalies and 
ambiguities in its guidelines because it will be able to resolve the issue practically 
rather than theoretically by actually examining and granting or denying patents. Its 
current practices are developing the law, albeit slowly and perhaps controversially, 
whereas European policy is more hypothetical. On the other hand the EU is in a 
beneficial position because it can watch and learn. While this does nothing to help 
resolve the issue it probably makes more practical sense in terms of effort and cost 
involved. The EU however, might be waiting a long time if it decides to be passive. 
There is already enough practice and action by the US, such as the guideline 
amendments, that the EU can draw on and develop itself. It may even come up with 
a better solution to what presently exists. A rehash of the morality debate however, 
might be cuase for concern for the EU. 
Both jurisdictions on paper at least may allow EST patents as long as applicants 
fulfil criteria. Whether this is desirable forms the basis of the next section of this 
paper. 
VII SHOULD ESTs BE PATENTED? 
On an analysis of the guidelines and criteria in both the US and the EU ESTs are 
patentable. That however, does not necessarily mean that they should be. The next 
question to consider therefore is whether patent offices should grant EST patents. 
This section of the paper will assess the arguments for and against the patenting of 
these DNA sequences and considers as a matter of policy whether it is desirable to 
allow patent offices to issue such patents. Many of the arguments are hypothetical 
and can therefore, not be backed up with concrete examples. This is mainly due to 
11 1 EU Directive above n86, article 6. 
the fact that patent offices have issued few, if any, real EST patents. Time might 
reveal the arguments to be unfounded or on the other hand well placed. 
Nevertheless, it might be better to resolve the issue theoretically and come to a 
conclusion that EST patents are not desirable under current practice rather than to 
take a "wait and see" approach. It would be much more difficult to try to stop EST 
patents after protection has been granted. If the effects, as argued below, occur then 
to decide beforehand that ESTs should not be patented is, for practical reasons, the 
most advantageous option. 
Many of the concerns that the public vented on the EST debate are difficult to 
include in a simple amendment to patent guidelines. They concern deeper and more 
fundamental issues. The concerns therefore might be better addressed through 
legislative change, which might even include the drastic step of banning the 
patenting of ESTs completely. Before such change is possible or even desirable it 
might pay to closely scrutinise developments in the area to see if in fact they do 
have the contended effects. 
A Infringement 
Probably the biggest practical issue that faces EST patents is the scope of protection 
of such patents and the issue of infringement. As the US PTO has issued only five 
EST related patents so far and as none of them has been opposed or disputed in 
court the jurisprudence on the subject is not yet in existence. As a result, it remains 
unclear what would constitute infringement of an EST patent and similarly what 
other potential patents and activities EST patents might infringe. Although one 
could make an educated guess as to what would constitute infringement, there is no 
unequivocal statement that concludes the matter. Similarly, one might also 
determine that the scope of protection of certain EST application under current 
practice would be extremely broad. However, without clear guidance from the 
courts, the legislature or patent offices, that issue remains uncertain as well. 
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The essence of the infringement argument is that since an EST is derived from a 
cDNA, it is only a small part of a more useful whole. If that EST then has patent 
protection it could potentially exclude uses of other DNA strands that contain the 
same EST sequence. A company that holds the rights to the EST may be able to 
exert influence over anyone who uses the EST either directly or even over someone 
who uses it inadvertently because it is contained in a larger cDNA strand. It is 
unclear whether use of a DNA strand that contains the EST would constitute 
infringement, especially if the patent has broad and general wording. Nevertheless, 
it remains a distinct possibility. Furthermore, the nature of ESTs is that they derive 
from a cDNA. Consequently, there may be numerous companies holding rights to 
ESTs from a single strand. What courts will do when it comes to these competing 
claims is speculative so until such claims are challenged in court the issue is 
unsettled. 
1 Broad rights 
Despite the tougher guidelines in the US concerning written requirement and utility 
it is still possible for an application to be worded such that it would suffice the 
requirements but have a broad scope if the PTO awarded patent protection. In 
addition, the situation in the EU is even less developed or clear. The Japan 
Bioindustry Association contends that 112 
it is not clear according to the present judicial cases whether the scope of the 
right would be limited to the ESTs having the specific sequence or would 
further encompass cDNAs including the full length nucleotide sequence of 
which the structure and function were unknown at the time of the EST 
application. 
Furthermore, the Human Genome Organisation (HUGO) has expressed senous 
concerns about the negative impact on further progress of genomic research and 
successful exploitation of its results should patent offices issue patents for broad 
112 Japan Biotechnology Association Opinions Concerning Patentability of DNA Fragments, 
http://www.jba.or.jp/katudou/topics/news9904l9e.html, (last accessed 29 August 2000). 
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claims of "comprising" type EST applications.
113 It also reiterates a statement it 
made in 1997 urging patent offices that intended on issuing EST patents 
114 
to rescind these decisions and, pending this, to strictly limit their claims to 
specified uses , since it would be untenable to make all subsequent innovation 
in which EST sequences would be involved in one way or another dependant 
on such patents 
To further clarify, as discussed above,
115 using the word "comprise" in a claim, as 
defined in the examining manual,
116 could have the effect that an EST patent that 
disclosed its sequence would also include the cDNA from which it is derived but 
also any other DNA strand that had the same sequence as the EST somewhere 
along its chain. This would create an extremely broad ambit of patent protection. 
Prima facie a patent office could refuse any other claim to a full cDNA patent that 
contained the EST sequence because that would infringe the EST patent already in 
existence. Courts might also uphold the rights of the EST patent holder in cases 
where researchers have used and developed cDNAs that inadvertently contained the 
EST strand. This is an undesirable outcome for, as discussed more fully below,
117 it 
is an unreasonable fetter on research and development. 
If an EST patent would preclude other patents for more important and useful 
sequences or would catch inadvertent infringement then that is a compelling reason 
for not allowing patent offices to issue them. Until there is a clear and settled rule 
about the scope of ESTs patent offices should be very wary about what protection 
they actually grant. They should in fact do more than that and create a clear and 
settled rule that would properly restrict an EST patent's ambit. 
113HUGO Statement on Patenting of DNA Sequences - In Particular Response to the European 
Biotechnology Directive, April 2000, http://www.gene.ucl.ac.uk/hugo/patent2000.html. 
[HUG02000] 
114 HUG02000, above nl 13 . 
11 5 See 2. "Written description " and the Revised Interim Guidelines above, 16. 
116 US Department of Commerce, Patent and Trademark Office, Manual of Patent Examining 
Procedure (6th ed 1996) 
11 7 See B. Research Will Be Hindered, below, 45 . 
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2 Courts 
One author118 has stated that US courts at least, would be likely to invalidate broad 
claims. This is because they would not accord with the ruling in Eli Lilly that the 
patent must disclose the DNA sequence of an entire protein-coding DNA segment 
to meet the written description requirement for claims that encompass that entire 
DNA segment. 119 However, as emphasised earlier, claims, which use wording to the 
likes of a "DNA molecule comprising sequence X" would seemingly comport with 
the court's gloss on the written description requirement 120 and would therefore gain 
wide patent protection. 
Of course, a court in future might invalidate such a broad claim, but on present 
guidelines and rulings the PTO can grant such broad protection and the patent 
would be valid. Furthermore, a court will probably only be able to invalidate 
patents that actually come before it. If its rulings did have the effect of invalidating 
other patents, it would be likely that the holders would litigate or demand for re-
examination of their claims. This would not only be costly but would involve a 
huge waste of time. It would be better therefore, that the PTO cleared the issue 
before it granted any protection rather than wait until after the fact by which time it 
would be too late. 
On this point, HUG0 121 
Stresses ... the necessity that patent offices and courts, when examining the 
requirement of industrial application of the claimed DNA molecules and their 
sequences to require an unambiguous indication and enabling disclosure of 
the function and to rigorously examine the indication of functions or the 
function disclosed. (emphasis in original) 
118 Emanuel Vacchiano "It's a Wonderful Genome: The written description requirement protects the 
human genome from overly broad patents" 32 J Marshall L Rev 805, 824. [Vacchiano] 
119 Eli Lilly, above n45 . 
120 See Bent, above n50. 
121 See HUG02000 above nl 13. 
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The statement perhaps does not go far enough. Patent offices should make it 
unequivocally clear what language used in a claim is and is not acceptable. It does a 
disservice to the industry to allow applications that would seemingly comport with 
current requirements but to then disallow the application for a reason not known to 
an applicant at the time of filing or to have a court invalidate the patent. 
3 Companies exerting influence 
Another consequence of broad protection is that companies that invest little time 
and effort into the research and development of ESTs may exert disproportional 
influence on other companies, which might continue further and more meaningful 
research. EST patents have the power to control development of the EST that may 
lead to a potential medical breakthrough without significantly contributing to the 
achievement. 122 
It would be ironic and unfortunate if the patent system were to reward the 
routine while discouraging the innovative. Yet that could be the result of 
offering broad patent rights to those who undertake massive but routine 
sequencing efforts- whether for ESTs or full genes- while granting more 
limited rights or no rights to those who make the far more difficult and 
significant discoveries of underlying biological functions.
123 
Companies will be unwilling to invest in research and development if EST patent 
holders can fetter their efforts, or their final products will receive less intellectual 
property protection because at an earlier stage some company got protection for a 
very minor part of the overall product development. Again, lawmakers should 
amend provisions so that such results will not occur. 
122 Vacchiano above nl 18, 822. 
123 HUGO Statement on the Patenting of DNA Sequences (1995) 
http://www.gene.ucl.ac.uk/hugo/patent.htm 
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4 Cross-claims from a common cDNA 
A further concern related to infringement is that many different ESTs may be 
extracted from one common cDNA and by many different companies. In addition, 
many genes belong to gene families so that one EST may recognise more than one 
gene. 124 Depending on the wording and scope of each patent there is huge potential 
that one claim will infringe another. Each company that had broad protection for 
their EST could potentially control the cDNA from which it is derived. A cDNA 
could technically end up with a vast number of contested controllers and therefore 
infringers. This would undoubtedly lead to complicated litigation. 
EST patents have the potential to be very broad. Guideline changes have not 
cleared up the matter and may have even compounded the problem by seemingly 
allowing anomalous results. On this basis therefore, EST patents under current 
policies in the US and EU should not be granted until infringement issues are 
finally settled. 
B Research Will Be Hindered 
A consequence of uncertainty concerning infringement is that it has the potential to 
hinder research. Companies may not be willing to begin, continue or invest in 
research if their products or developments will infringe an EST patent or EST 
patent holders might obstruct their efforts. Moreover, legal battles that could ensue 
due to the ambiguity and uncertainty that surrounds the infringement issue might 
eat up resources more properly spent on research and development. 
Issuing EST patents that might hinder research and development in the 
biotechnology industry is a fundamental problem, which strikes at the heart of the 
justifications of patent law in general. The monopoly-profit-incentive thesis, which 
is the most widely supported justification for allowing patents, states that economic 
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growth is inherently desirable and can be achieved by encouraging new technology 
and invention. Supply of invention would be less if there were no incentives such as 
patents for monopoly, which would in turn lead to less economic and industrial 
progress. 125 
Patents for ESTs go against this "encouragement" doctrine for they have the 
potential to cripple research and development of the entire human genome. Apart 
from the infringement and legal battle issues there are a number of reasons why this 
is so. 
1 Royalties 
The first reason concerns royalties. Smaller companies, non-profit research 
facilities and academic institutions usually always have limited resources and might 
be discouraged from entering into the development of diagnostics and therapeutics 
because of the costs associated with using patented research data. 126 Research is 
extremely expensive in the first place. To impose an obligation on such institutions 
to pay a royalty at the very beginnings of their research that might bear no useful 
results is unduly harsh. Such a royalty or even the obligation to apply for a licence 
for something as trivial as an EST will discourage rather than encourage further 
research. 
There is evidence that in the case of whole genes researchers and scientists are 
receiving demands from the patent holders for royalties. For example, Myriad 
Genetics of Salt Lake City in the US has already cracked down on laboratories that 
124 ASHG paper above n28. 
125 S Ricketson & M Richardson Intellectual Property: Cases, Materials and Commentary 2nd Ed 
(Butterworths, Australia 1998) 555. 
126 Human Genome Project Information 
http://www.ornl.govffechResources/Human_Genome/elsi/patents.html (last accessed 24 August 
2000) [HGPI] 
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have tested for the breast cancer gene BRCAl without paying licensing fees. 127 If 
researchers had to pay for the use of EST sequences as well, the costs of research 
might increase unjustifiably. 
2 Patent-stacking 
Costs may also increase as time passes due to "patent stacking". This is where 
single DNA sequences have many patents applying to them such as EST, whole 
gene, or single nucleotide polymorphism patents. 128 Each separate company that 
owns the patent might impose some kind of fee for the use of their part of the DNA 
sequence. Not only would this be expensive, but the time wasted applying to use 
the sequence for research in the first place and the time spent working out if a 
patent would even apply would undoubtedly encourage researchers to give up and 
try something else. The effect of this on patent holders might be negative as well 
for instead of making a profit off their intellectual property no one would be willing 
to pay for such a trivial use. The EST patent therefore becomes all but useless. 
In reality, companies store their ESTs in large databases and license the use of them 
to other institutions that wish to further their research. At present, because the vast 
majority of ESTs have no patent protection, companies are not justified in charging 
large amounts of money for access. Researchers may also source an EST elsewhere 
if costs are high without the threat of infringing any intellectual property right. 
However, once an EST receives protection, database access fees may soar, for 
companies would then have a monopoly. This again would kill off research and 
would keep the valuable information in the hands of large companies who can 
afford access or who agree to some kind of reciprocal access arrangements. This 
outcome falls far short of the "encouragement of industry doctrine" that patent law 
is based on. 
127 Nell Boyce and Andy Coghlan "Your genes in their hands" New Scientist 20 May 2000 no2239, 
15 . [Boyce] 
128 See Murray above n25, 254 and HGPI above nl26. 
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The ASHG makes some interesting observations regarding the research issue. It is 
useful to quote their ideas in full. 129 
Normally, a patent ensures that a gene will be available for all researchers and 
for any company willing to license it. We fear that in the case of ESTs it may 
have quite the opposite effect. An EST patent, to be useful to the commercial 
sector, must make broad claims in regard to future use, including protection 
for the rest of the gene and its protein product, and their use for diagnostic and 
therapeutic applications. The academic community is unlikely to put major 
research effort into an EST-identified gene or its product if someone else 
already has the right to license its use based on the trivial effort required to 
sequence the original EST. In the commercial sector there may be reluctance 
to invest heavily in further research on EST-identified genes when a small but 
unknown fraction of them will turn out to have commercial utility, and when 
the useful ones may be contested by patents involving other ESTs from the 
same gene. Genome research could end at the level of ESTs 
Research and development works on the basis that the fundamental initial research 
tools should be widely and freely available. By, in effect, taking away tools with 
which to work research cannot proceed. As the ASHG states, the consequence of 
this is that genomic research will end at the beginning. There will be no impetus to 
carry on research to develop gene-based therapies and products if there is a myriad 
of intellectual property to wade through, especially at the very beginnings of the 
research process. Either that, or companies will pass costs associated with this extra 
burden on to the public. The effects of that however, are that many people will be 
unwilling or even unable to pay for gene products and will become disenchanted 
with the whole intellectual property regime. Both the public and the biotechnology 
industry will demand some kind of change if the intellectual property system is to 
survive. 
HUGO also agrees that EST patents might have such effects.130 
129 ASHG paper, above n28. 
130 HUG02000 above nll3. 
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.. . reach-through patent claims and reach-through licences, as partly accepted 
in the current practice, will not only seriously affect further research and 
development but could, eventually, discredit the entire patent system as an 
invaluable incentive to invent, innovate and invest in new technologies. 
(Emphasis in original) 
To lock up so much information at the very start of the research process is an 
objectionable move. Patent offices should have the foresight to realise that under 
the present policies the negative impacts of granting patent protection over ESTs 
will far outweigh any benefit to society or the biotechnology industry. Such 
potential negative effects call for a much stricter review of current patent 
requirements when it comes to these partial DNA sequences. 
C Minor Arguments 
The minor though just as compelling arguments state that patents are replacing 
journal articles as places for public disclosure, which is having the effect of 
reducing the body of knowledge in literature. 131 This cannot be good for science in 
terms of both practicality and the wide dissemination of useful knowledge. 
Additionally, due to the competition that the race to patent ESTs and other gene 
related discoveries creates, researchers might become less willing to cooperate and 
share information until after they have secured patent protection. This undoubtedly 
leads to duplication of effort rather than preventing such duplication as some might 
argue and again hinders the research process. 132 
D Arguments for allowing EST patents 
The arguments for allowing EST protection are far less compelling. The one most 
often stated, like that for justifying any patent, is that unless companies can get a 
monopoly on their inventions to recover costs of research and development 
companies will not invent at all. This argument can be quickly disposed of (1) by 
13 1 HGPI above nl 26. 
132 HGPI above nl26. 
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showing that patenting of ESTs will in effect hinder research as opposed to 
encouraging it, as discussed above and (2) ESTs require minimal inventiveness, if 
any. Craig Venter, the president of Celera Genomics, a major genomics company 
and gene patent filer, states that the combination of free HGP database access, 
liberal patent requirements and simple computer sequencing, has enabled lots of 
companies to file a patent "without doing any work." 133 This shows that ESTs are 
still extremely easy to discover and obtain and that despite no protection as yet, 
companies still "invent" them. 
On balance therefore the arguments for disallowing protection for ESTs in their 
present form far outweigh the arguments for allowing them. Until the issue of 
infringement has been resolved and until such a system whereby ESTs will not 
stymie research has been created, patent offices should hold off issuing any 
protection for EST patents. 
E Solutions? 
There is no easy solution to the EST debate. It will involve well-informed 
discussion and will balance the rights of researchers and the public with the rights 
of the for-profit companies that rely so heavily on intellectual property protection. 
Vacchiano contends that 134 
the greatest value of ESTs may not lie in the individual ESTs, but may lie in the 
synergism of EST data in functional EST databases. Optimally then, patent 
protection awarded for ESTs must promote the construction and expansion of EST 
databases. 
This may be a solution to problems associated with individual ESTs but it might 
possibly raise issues concerning database protection. It seems a better option 
however than doing nothing at all. The best option would be to follow the likes of 
the SNP Consortium, which was set up in April 1999 to make information related 
133 Boyce above nl27, 15. 
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to single nucleotide polymorphisms (SNPs) 135 available to the public without 
intellectual property restrictions. The Consortium involves a number of well-
established companies, 136 which publish information concerning SNPs the moment 
it is discovered. The information is then posted on a website in the form of a freely 
accessible database. The same could happen with companies that discover ESTs. 
Instead of trying to patent each single EST, if companies worked together to form a 
larger database that everyone could access then many of the problems would 
disappear. Patent offices would not have to worry about issuing controversial 
patents and research would proceed unhindered. New alliances might be formed 
with the spirit of cooperation. However, the way the issue is moving at present that 
seems an unlikely result. 
In any case, patent offices will examine EST patents in the near future. Before they 
begin however, they should undertake a comprehensive review of the requirements 
for patentability. In this age of competition and emerging technologies more and 
more people will want protection for their ideas. The current threshold is far too 
low. In light of the above discussion patent offices should further tighten the 
requirements for industrial applicability and utility, and they should make clear that 
certain ambiguous language such as "comprising" is not acceptable in a patent 
application. Claimants should receive protection only for what they have disclosed 
and the protection should be proportionate to the time and effort involved in (1) 
discovering the invention and (2) putting together an application. If protection for 
ESTs is granted under current policy, the level of protection is disproportionate to 
the effort involved and to the contribution to science in general. 
134 Vacchiano, above nl 18, 822. 
135 Single nucleotide polymorphisms are DNA sequence variations among groups of individuals and 
have great significance for biomedical research. See http://snp.cshl.org/index.html (last accessed 15 
September 2000). 
136 For example, Glaxo-Wellcome, Roche, Bayer, Novartis and SmithKline Beecham. 
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VIII CONCLUSION 
Under the new US guidelines and the new EU Directive, ESTs will still be 
patentable subject matter. Although the new rules have raised the bar a little they 
will not stop reworded and refiled claims. Despite the US issuing only five EST 
type patents and despite the EU having issued none, companies have issued 
thousands of claims that patent offices, sooner or later, will have to examine. The 
consequences of allowing patent protection for ESTs that have limited practical use 
as probes will lead to many problems in the biotechnology industry. Research will 
more than likely slow due to infringement and royalty issues. ESTs in their current 
form, although useful, have very little practical value on their own. They are far 
more useful in comparative databases. It would be advantageous to all involved in 
the biotechnology industry to seek protection of databases rather than individual 
ESTs or better still, to cooperate to form freely accessible databases so that more 
valuable research can be undertaken. In any case, patent offices should begin a 
comprehensive review of their policy in light of the above discussion so as to 
tighten further the requirements of a grant for patent protection. 
The US and the EU will begin to examine EST applications in the near future. Until 
their decisions are known the patentability of ESTs is in a state of flux. 
Theoretically ESTs are patentable and theoretically EST patents could have 
disastrous results and should not therefore, be patentable. Companies that exert 
little effort on small claims could potentially control entire genes and receive big 
gains. Like any new issue, time will only tell. 
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